A Randomized Controlled Study of the Efficacy and Safety of Lenalidomide in the Treatment of Active IgG4-related Disease

NCT07068165 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

RECRUITING

Status

198

Enrollment

OTHER

Sponsor class

Conditions

IgG4 Related Disease

Interventions

DRUG: 5mg lenalidomide
DRUG: 10mg lenalidomide
DRUG: Prednisone monotherapy

Sponsor

Peking Union Medical College Hospital